Blum Manuel R, Bauer Douglas C, Collet Tinh-Hai, Fink Howard A, Cappola Anne R, da Costa Bruno R, Wirth Christina D, Peeters Robin P, Åsvold Bjørn O, den Elzen Wendy P J, Luben Robert N, Imaizumi Misa, Bremner Alexandra P, Gogakos Apostolos, Eastell Richard, Kearney Patricia M, Strotmeyer Elsa S, Wallace Erin R, Hoff Mari, Ceresini Graziano, Rivadeneira Fernando, Uitterlinden André G, Stott David J, Westendorp Rudi G J, Khaw Kay-Tee, Langhammer Arnuf, Ferrucci Luigi, Gussekloo Jacobijn, Williams Graham R, Walsh John P, Jüni Peter, Aujesky Drahomir, Rodondi Nicolas
Department of General Internal Medicine, Inselspital, Bern University Hospital, Bern, Switzerland.
Departments of Medicine and Epidemiology and Biostatistics, University of California, San Francisco.
JAMA. 2015 May 26;313(20):2055-65. doi: 10.1001/jama.2015.5161.
Associations between subclinical thyroid dysfunction and fractures are unclear and clinical trials are lacking.
To assess the association of subclinical thyroid dysfunction with hip, nonspine, spine, or any fractures.
The databases of MEDLINE and EMBASE (inception to March 26, 2015) were searched without language restrictions for prospective cohort studies with thyroid function data and subsequent fractures.
Individual participant data were obtained from 13 prospective cohorts in the United States, Europe, Australia, and Japan. Levels of thyroid function were defined as euthyroidism (thyroid-stimulating hormone [TSH], 0.45-4.49 mIU/L), subclinical hyperthyroidism (TSH <0.45 mIU/L), and subclinical hypothyroidism (TSH ≥4.50-19.99 mIU/L) with normal thyroxine concentrations.
The primary outcome was hip fracture. Any fractures, nonspine fractures, and clinical spine fractures were secondary outcomes.
Among 70,298 participants, 4092 (5.8%) had subclinical hypothyroidism and 2219 (3.2%) had subclinical hyperthyroidism. During 762,401 person-years of follow-up, hip fracture occurred in 2975 participants (4.6%; 12 studies), any fracture in 2528 participants (9.0%; 8 studies), nonspine fracture in 2018 participants (8.4%; 8 studies), and spine fracture in 296 participants (1.3%; 6 studies). In age- and sex-adjusted analyses, the hazard ratio (HR) for subclinical hyperthyroidism vs euthyroidism was 1.36 for hip fracture (95% CI, 1.13-1.64; 146 events in 2082 participants vs 2534 in 56,471); for any fracture, HR was 1.28 (95% CI, 1.06-1.53; 121 events in 888 participants vs 2203 in 25,901); for nonspine fracture, HR was 1.16 (95% CI, 0.95-1.41; 107 events in 946 participants vs 1745 in 21,722); and for spine fracture, HR was 1.51 (95% CI, 0.93-2.45; 17 events in 732 participants vs 255 in 20,328). Lower TSH was associated with higher fracture rates: for TSH of less than 0.10 mIU/L, HR was 1.61 for hip fracture (95% CI, 1.21-2.15; 47 events in 510 participants); for any fracture, HR was 1.98 (95% CI, 1.41-2.78; 44 events in 212 participants); for nonspine fracture, HR was 1.61 (95% CI, 0.96-2.71; 32 events in 185 participants); and for spine fracture, HR was 3.57 (95% CI, 1.88-6.78; 8 events in 162 participants). Risks were similar after adjustment for other fracture risk factors. Endogenous subclinical hyperthyroidism (excluding thyroid medication users) was associated with HRs of 1.52 (95% CI, 1.19-1.93) for hip fracture, 1.42 (95% CI, 1.16-1.74) for any fracture, and 1.74 (95% CI, 1.01-2.99) for spine fracture. No association was found between subclinical hypothyroidism and fracture risk.
Subclinical hyperthyroidism was associated with an increased risk of hip and other fractures, particularly among those with TSH levels of less than 0.10 mIU/L and those with endogenous subclinical hyperthyroidism. Further study is needed to determine whether treating subclinical hyperthyroidism can prevent fractures.
亚临床甲状腺功能障碍与骨折之间的关联尚不清楚,且缺乏临床试验。
评估亚临床甲状腺功能障碍与髋部、非脊柱、脊柱或任何骨折之间的关联。
检索MEDLINE和EMBASE数据库(建库至2015年3月26日),不限语言,查找有甲状腺功能数据及后续骨折情况的前瞻性队列研究。
从美国、欧洲、澳大利亚和日本的13个前瞻性队列中获取个体参与者数据。甲状腺功能水平定义为甲状腺功能正常(促甲状腺激素[TSH],0.45 - 4.49 mIU/L)、亚临床甲状腺功能亢进(TSH < 0.45 mIU/L)和亚临床甲状腺功能减退(TSH≥4.50 - 19.99 mIU/L)且甲状腺素浓度正常。
主要结局为髋部骨折。任何骨折、非脊柱骨折和临床脊柱骨折为次要结局。
在70298名参与者中,4092名(5.8%)有亚临床甲状腺功能减退,2219名(3.2%)有亚临床甲状腺功能亢进。在762401人年的随访期间,2975名参与者(4.6%;12项研究)发生髋部骨折,2528名参与者(9.0%;8项研究)发生任何骨折,2018名参与者(8.4%;8项研究)发生非脊柱骨折,296名参与者(1.3%;6项研究)发生脊柱骨折。在年龄和性别调整分析中,亚临床甲状腺功能亢进与甲状腺功能正常相比,髋部骨折的风险比(HR)为1.36(95%CI,1.13 - 1.64;2082名参与者中有146例事件,56471名参与者中有2534例);任何骨折的HR为1.28(95%CI,1.06 - 1.53;888名参与者中有121例事件,25901名参与者中有2203例);非脊柱骨折的HR为1.16(95%CI,0.95 - 1.41;946名参与者中有107例事件,21722名参与者中有1745例);脊柱骨折的HR为1.51(95%CI,0.93 - 2.45;732名参与者中有17例事件,20328名参与者中有255例)。较低的TSH与较高的骨折率相关:TSH小于0.10 mIU/L时,髋部骨折的HR为1.61(95%CI,1.21 - 2.15;510名参与者中有47例事件);任何骨折的HR为1.98(95%CI,1.41 - 2.78;212名参与者中有44例事件);非脊柱骨折的HR为1.61(95%CI,0.96 - 2.71;185名参与者中有32例事件);脊柱骨折的HR为3.57(95%CI,1.88 - 6.78;162名参与者中有8例事件)。在调整其他骨折危险因素后,风险相似。内源性亚临床甲状腺功能亢进(不包括使用甲状腺药物者)与髋部骨折的HR为1.52(95%CI,1.19 - 1.93)、任何骨折的HR为1.42(95%CI,1.16 - 1.74)以及脊柱骨折的HR为1.74(95%CI,1.01 - 2.99)相关。未发现亚临床甲状腺功能减退与骨折风险之间存在关联。
亚临床甲状腺功能亢进与髋部及其他骨折风险增加相关,尤其是TSH水平小于0.10 mIU/L者以及内源性亚临床甲状腺功能亢进者。需要进一步研究以确定治疗亚临床甲状腺功能亢进是否可预防骨折。